| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | — | 3.2 |
| Net income | -8.1 | -7.7 |
| EPS (diluted, $ a share) | $-1.94 | $-9.86 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: CRIS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Curis Inc: key numbers
- Share price
- $0.4358Close, Nov 16
- Market cap
- $4.15M
- Shares outstanding
- 9.51MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Curis Inc
All →Curis Financial Results
Curis reported financial results for the third quarter of 2026 and provided an operational update on its TakeAim CLL and TakeAim Lymphoma clinical trials. The company highlighted progress in combining emavusertib with BTK inhibitors for the treatment of CLL and PCNSL, with initial data from the TakeAim CLL study expected in December 2026.
- Term
- Q3 2026
“The excitement among clinicians and patients reflects the clear unmet need in both CLL and PCNSL, where emavusertib has the potential to change the treatment landscape when combined with approved BTK inhibitors.”
James Dentzer, Chief Executive Officer of Curis
Curis Nasdaq/NYSE Compliance Notice
Curis, Inc. received a delisting determination letter from Nasdaq on November 2, 2026, because its common stock closed below the $1.00 minimum bid price for 30 consecutive business days. Due to a previous 1-for-20 reverse stock split in July 2026 and an existing Panel Monitor, the company is not eligible for a standard compliance period and faces immediate delisting risk. The company intends to appeal the decision to a Nasdaq Hearings Panel to stay the delisting process.
- Counterparty
- Nasdaq
Curis Capital Raise of $8.5M
Curis, Inc. entered into a securities purchase agreement to raise approximately $8.5 million through the sale of 16,666,680 shares of common stock (or pre-funded warrants) and accompanying common warrants at a combined price of $0.51 per share. The company intends to use the proceeds to fund research and development activities, specifically to support operations through its initial Chronic Lymphocytic Leukemia (CLL) data readout expected in December 2026.
- Value
- $8.5M